Weeks after dropping big response data, Amgen lines up priority review for KRAS hopeful sotorasib in NSCLC
Amgen is looking to go where no other drugmaker has gone before with the KRAS inhibitor sotorasib, which posted big Phase II lung cancer response data in late January. The FDA has been listening, and now it’s ready to give Amgen its ear.
The FDA will speedily review sotorasib’s application to treat second-line patients with locally advanced or metastatic non-small cell lung cancer in what would be the first successful bid to inhibit KRAS, Amgen said in a release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.